Table 4.
Clinicopathological characteristics of the patients before and after propensity score matching
| Variable | Before matching | After matching | ||||
|---|---|---|---|---|---|---|
| CAR ≤0.027 (N = 301) | CAR >0.027 (N = 177) | P value | CAR ≤0.027 (N = 124) | CAR >0.027 (N = 124) | P value | |
| Age, y (≤70/>70) | 161/140 (53.5/46.5) | 92/85 (52/48) | .776 | 61/63 (49.2/50.8) | 67/57 (54/46) | .525 |
| Gender (male/female) | 221/80 (73.4/26.6) | 146/31 (82.5/17.5) | .025 | 98/26 (79/21) | 98/26 (79/21) | 1 |
| BMI, kg/m2 (≤22/>22) | 132/169 (43.8/56.2) | 60/116 (34.1/65.9) | .042 | 41/83 (33/67) | 48/76 (38.7/61.3) | .427 |
| HBV (N/Y) | 243/56 (81.3/18.7) | 157/19 (89.2/10.8) | .026 | 109/15 (87.9/12.1) | 108/16 (87.1/12.9) | 1 |
| HCV (N/Y) | 120/180 (40/60) | 102/75 (57.6/42.4) | <.001 | 62/62 (50/50) | 61/63 (49.2/50.8) | 1 |
| Plt, ×104/mm3 (≥14/<14) | 123/178 (40.9/59.1) | 113/64 (63.8/36.2) | <.001 | 65/59 (52.4/47.6) | 70/54 (56.5/43.5) | .611 |
| PT, % (≥80/<80) | 229/71 (76.3/23.7) | 123/54 (69.5/30.5) | .106 | 91/32 (74/26) | 91/33 (73.4/26.6) | 1 |
| T‐Bil, mg/dL (≤1/>1) | 254/47 (84.4/15.6) | 142/35 (80.2/19.8) | .259 | 105/19 (84.7/15.3) | 101/23 (81.5/18.5) | .611 |
| AST, IU/L (≤35/>35) | 181/119 (60.3/39.7) | 93/84 (52.5/47.5) | .103 | 75/49 (60.5/39.5) | 64/60 (51.6/48.4) | .201 |
| ALT, IU/L (≤34/>34) | 195/106 (64.8/35.2) | 105/72 (59.3/40.7) | .241 | 87/37 (70.2/29.8) | 77/47 (62.1/37.9) | .227 |
| ICGR15, % (≤15/>15) | 172/124 (58.1/41.9) | 95/79 (54.6/45.4) | .499 | 62/62 (50/50) | 66/58 (53.2/46.8) | .703 |
| AFP, ng/mL (≤10/>10) | 163/134 (54.9/45.1) | 89/86 (50.9/49.1) | .444 | 77/47 (62.1/37.9) | 66/57 (53.7/46.3) | .198 |
| DCP, mAU/mL (≤100/>100) | 205/92 (69/31) | 86/90 (48.9/51.1) | <.001 | 77/47 (62.1/37.9) | 73/51 (58.9/41.1) | .696 |
| Child‐Pugh (A/B) | 283/17 (94.3/5.7) | 156/21 (88.1/11.9) | .021 | 113/11 (91.1/8.9) | 113/11 (91.1/8.9) | 1 |
| Liver damage (A/B, C) | 227/67 (77.2/22.8) | 118/57 (67.4/32.6) | .023 | 85/39 (68.6/31.4) | 88/36 (71/29) | .782 |
| Tumor number (1/>1) | 205/96 (68.1/31.9) | 106/71 (59.9/40.1) | .074 | 86/38 (69.4/30.6) | 75/49 (60.5/39.5) | .183 |
| Tumor size, mm (≤50/>50) | 272/29 (90.4/9.6) | 115/61 (65.3/34.7) | <.001 | 102/22 (82.3/17.7) | 102/22 (82.3/17.7) | 1 |
| Anatomical resection (Y/N) | 98/203 (32.6/67.4) | 44/132 (25/75) | .096 | 39/85 (31.5/68.5) | 39/85 (31.5/68.5) | 1 |
| Operation time, min (≤300/>300) | 147/150 (49.5/50.5) | 64/112 (36.4/63.6) | .005 | 59/65 (47.6/52.4) | 54/70 (43.6/56.4) | .611 |
| Blood loss, mL (≤1000/>1000) | 277/22 (92.6/7.4) | 149/27 (84.7/15.3) | .007 | 114/10 (91.9/8.1) | 112/12 (90.3/9.7) | .823 |
| MVI (N/Y) | 250/51 (83.1/16.9) | 131/46 (74/26) | .018 | 98/26 (79/21) | 93/31 (75/31) | .546 |
| LC (N/Y) | 209/78 (72.8/27.2) | 116/45 (72.1/27.9) | .912 | 82/32 (71.9/28.1) | 77/39 (66.4/33.6) | .393 |
| Histological grade | ||||||
| Well, moderately differentiated/poorly differentiated | 271/22 (92.5/7.5) | 135/30 (81.8/18.2) | <.001 | 99/17 (85.3/14.7) | 105/9 (92.1/7.9) | .144 |
| IM (N/Y) | 242/41 (85.5/14.5) | 153/12 (92.7/7.3) | .023 | 114/10 (91.9/8.1) | 112/12 (90.3/9.7) | .823 |
AFP, alpha‐fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CAR, C‐reactive protein to albumin ratio; DCP, des‐gamma‐carboxyprothrombin; HBV, hepatitis B virus; HCV, hepatitis C virus; ICGR15, indocyanine green retention rate at 15 min; IM, intrahepatic metastasis; LC, liver cirrhosis; LMR, lymphocyte to monocyte ratio; MVI, microvascular invasion; Plt, platelet count; PT, prothrombin time; T‐Bil, total bilirubin.